Pfizer Inc. joined the migraine market competition on 9 November via a deal bringing it ex-US commercial rights to Biohaven Pharmaceutical Holding Company Ltd.’s Nurtec ODT (rimegepant) as well as a follow-on oral calcitonin gene-related peptide (CGRP) inhibitor for $500m up front. With significant earnout potential, the agreement strengthens Biohaven financially, removes its financial risk for commercializing Nurtec overseas and gives it a commercial partner with broad access and experience outside the US.
Biohaven Gets Pfizer’s Help To Make Nurtec An Ex-US Success Story Too
As the only oral CGRP migraine therapy approved for both prevention and acute therapy, Nurtec has taken significant US market share. Biohaven will call on Pfizer’s expertise and contacts to repeat that success abroad.
More from Deals
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
More from Business
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
• By
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.